Myasthenia gravis – current treatment standards and emerging drugs
Authors:
Markéta Komlóová 1; Kamil Musílek 2,4; Kamil Kuča 3,4
Authors‘ workplace:
Univerzita Karlova v Praze, Farmaceutická fakulta Hradec Králové, Katedra farmaceutické chemie a kontroly léčiv
1; Univerzita obrany Hradec Králové, Fakulta vojenského zdravotnictví, Katedra toxikologie
2; Univerzita obrany Hradec Králové, Fakulta vojenského zdravotnictví, Centrum pokročilých studií
3; Fakultní nemocnice Hradec Králové
4
Published in:
Čes. slov. Farm., 2011; 60, 47-53
Category:
Review Articles
Overview
Myasthenia gravis is very rare autoimmune disease of neuromuscular junction, which presents as a weakness and increased fatiquability of striated muscles. Formerly, myasthenia was largely constraining disease and often ended by death. Recently, advanced diagnostic methods and variety of therapeutic options allow the full compensation of the disease and the quality of patient life is restored. In this review, the methods used during the myasthenia treatment along with the description of the disease itself were detailed.
Key words:
myasthenia gravis – review – diagnostics – treatment – emerging drugs
Sources
1. Willis, T.: De anima brutorum. Oxford, UK: Theatro Sheldoniano 1672; 404–406.
2. Schmidt, J. E.: Medical Discoveries, Who and When, Springfield, Illinois. USA: Thomas 1959.
3. Barohn, R. J.: Treatment and clinical research in myasthenia gravis. Ann. NY Acad. Sci. 2008; 1132, 225–232.
4. Carr, A. S., Cardwell, C. R., McCarron, P. O., McConville, J.: A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol. 2010; 10(1), 46.
5. Phillips, L. H., Torner, J. C.: Epidemiologic evidence for changing natural history of myasthenia gravis. Neurology 1996; 47, 1233–1238.
6. Špalek, P.: Myasténia gravis. Cesk. Slov. Neurol. 2008; 71, 7–24.
7. Toyka, K. V., Drachman, D. B., Griffin, D. E.: Myasthenia gravis: study of humoral immune mechanisms by passive transfer to mice. N. Engl. J. Med. 1977; 296, 125–131.
8. Santa, T., Engel, A. G., Lambert, E. H.: Histomeric study of neuromuscular junction ultrastructure I. Myasthenia gravis. Neurology 1972; 22, 71–82.
9. Lennon, V. A.: Serological diagnosis of myasthenia gravis and Lambert-Eaton myasthenic syndrome. Handbook of myasthenia gravis and myasthenic syndromes. New York: Marcel-Dekker 1994; 149–164.
10. Hoch, W., McConville, J., Helms, S.: Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nature Med. 2001; 7, 365–368.
11. Thanvi, B. R., Lo, T. C. N.: Update on myasthenia gravis. Postgrad. Med. J. 2004; 80, 690–700.
12. Warrell, D. A., Cox, T. M., Firth, J. D., Weatherall, D.: Oxford Texbook of Medicine. 4. vyd. Oxford: Oxford University Press 2003.
13. Pen, A. S., Low, B. W,, Jaffe, J. L.: Drug-induced autoimmune myastenia gravis. Ann. N Y Acad. Sci. 1998; 841, 433–449.
14. Juel, V. C., Massey, J. M.: Myasthenia gravis. Orphanet J. Rare Dis. 2007; 2, 44.
15. Bedlack, R. S., Sanders, D. B.: How to handle myasthenic crisis. Essential steps in patient care. Postgrad. Med. 2000; 107, 211–222.
16. Jablecki, A. 3rd, Barohn, R. J., Ernstoff, R. M.: Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000; 55, 16–23.
17. Oh, S. J., Kim, D. E., Kuruoglu, R.: Diagnostic sensitivity of the laboratory tests in myasthenia gravis. Muscle Nerve. 1992; 15, 720–724.
18. Lindstrom, J. M., Seybold, M. E., Lennon, V. A.: Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976; 26, 1054–1059.
19. Lindstrom, J.: An assay for antibodies to human acetylcholine receptor in serum from patients with myasthenia gravis. Clin. Immunol. Immunopathol. 1977; 7, 36–43.
20. Vincent, A., Newsom-Davis, J.: Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J. Neurol. Neurosurg. Psychiatry 1985; 48, 1246–1252.
21. Keesey, J. C.: Contemporary Opinions about Mary Walker. A shy pioneer of therapeutic neurology. Neurology 1998; 51, 1433–1439.
22. Hodge, A. S., Humphrey, D. R., Rosenberry, T. L.: Ambenonium is a rapidly reversible noncovalent inhibitor of acetylcholinesterase, with one of the highest known affinities. Mol. Pharmacol. 1992; 41, 937–942.
23. Komloova, M., Musilek, K., Dolezal, M., Gunn--Moore, F., Kuca, K.: Structure-activity relationship of quaternary acetylcholinesterase inhibitors – Outlook for early myasthenia gravis treatment. Curr. Med. Chem. 2010; 17, 1810–1824.
24. Musilek, K., Komloova, M., Zavadova, V., Holas, O., Hrabinova, M., Pohanka, M.: Preparation and in vitro screening of symmetrical bispyridinium cholinesterase inhibitors bearing different connecting linkage – initial study for myasthenia gravis implications. Bioorg. Med. Chem. Lett. 2010; 20, 1763–1766.
25. Musilek, K., Komloova, M., Holas, O., Hrabinova, M., Pohanka, M., Dohnal, V., Kuca, K.: Preparation and in vitro screening of symmetrical bis-isoquinolinium cholinesterase inhibitors bearing various connecting linkage – implications for early Myasthenia gravis treatment. Eur. J. Med. Chem. 2011; 46, 811– 818.
26. Seybold, M. E., Drachman, D. B.: Gradually increasing doses of prednisone in myasthenia gravis: reducing the hazards of treatment. N. Engl. J. Med. 1974; 290, 81–84.
27. Sghirlanzoni, A., Peluchetti, D., Mantegazza, R., Fiacchino, F., Cornelio, F.: Myasthenia gravis: prolonged treatment with steroids. Neurology 1984; 34, 170–174.
28. Pascuzzi, R. M., Coslett, H. B., Johns, T. R.: Long-term corticosteroid treatment of myasthenia gravis: Report of 116 patients. Ann. Neurol. 1984; 15, 291–298.
29. Johns, T. R.: Long-term corticosteroid treatment of myasthenia gravis. Ann. NY Acad. Sci. 1987; 505, 568–583.
30. Kokontis, L., Gutmann, L.: Current treatment of neuromuscular diseases. Arch. Neurol. 2000; 57, 939–943.
31. Schwendimann, R. N., Burton, E., Minagar, A.: Management of myasthenia gravis. Am. J. Ther. 2005; 12, 262–268.
32. Herrlinger, U., Weller, M., Dichgans, J., Melms, A.: Association of primary central nervous system lymphoma with long-term azathioprine therapy for myasthenia gravis. Ann. Neurol. 2000; 47, 682–683.
33. De Feo, L. G., Schottlender, J., Martelli, N. A., Molfino, N. A.: Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis. Muscle Nerve 2002; 26, 31–36.
34. Ciafaloni, E., Sanders, D. B.: Advances in myasthenia gravis. Curr. Neurol. Neurosci. Rep. 2002; 2, 89–95.
35. Chaudhry, V., Cornblath, D. R., Griffin, J. W., O’Brien, R., Drachman, D. B.: Mycophenolate mofetil: a safe and promising immunosupressant in neuromuscular diseases. Neurology 2001; 56, 94–96.
36. Konishi, T., Yoshiyama, Y., Takamori, M., Saida, T.: Long-term treatment of generalized myasthenia gravis with FK506 (tacrolimus). J. Neurol. Neurosurg. Psychiatry 2005; 76, 448–450.
37. Cwiertka, K., Trojanec, R., Špačková, K., Hajdúch, M.: Terapeutické monoklonální protilátky v onkologii. Klin. Farmakol. Farm. 2004; 18, 165–170.
38. Du, J., Yang, H., Zhang, D., Wang, J., Guo, H., Peng, B.: Structural basis for the blockage of IL-2 signaling by therapeutic antibody basiliximab. J. Immunol. 2010; 184, 1361–1368.
39. Sobotková, M., Bartůňková, J.: Monoklonální protilátky a další biologická léčiva užívaná v imunosupresivní léčbě. Remedia. 2008; 5, 18.
40. Kakoulidou, M., Pirskanen-Matell, R., Lefvert, A. K.: Treatment of a patient with myasthenia gravis using antibodies against CD25. Acta Neurol. Scand. 2008; 117, 211–216.
41. Madhusudan, S., Muthuramalingam, S. R., Braybrooke, J. P.: Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. J. Clin. Oncol. 2005; 23, 5950–5959.
42. Bongioanni, P., Ricciardi, R., Pellegrino, D., Romano, M. R.: T-cell tumor necrosis factor-alpha receptor binding in myasthenic crisis. J. Neuroimmunol. 1999; 93, 203–207.
43. Rowin, J., Meriggioli, M. N., Tüzün, E., Leurgans, S., Christadoss, P.: Etanercept treatment in corticosteroid-dependent myasthenia gravis. Neurology. 2004; 63, 2390–2932.
44. Soreq, H., Saidman, S., Saidman, J., Evron, T.: Antisense oligonucleotide against human acetylcholinesterase (AChE) and uses thereof. US patent 2006, US7074915.
45. Sussman, J.D., Argov, Z., McKee, D., Hazum, E., Brawer, S., Soreq, H.: Antisense treatment for myasthenia gravis: experience with monarsen, Ann. N Y Acad. Sci. 2008; 1132, 283–290.
46. Brenner, T., Hamra-Amitay, Y., Evron, T., Boneva, N.: The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis. FASEB J. 2003; 17, 214–222.
47. Legay, C. S., Bon, P., Vernier, F.: Cloning and expansion of a rat acetylcholinesterase subunit: generation of a Torpedo collagenic subunit. J. Neurochem. 1993; 60, 337–346.
48. Kaufer, D., Friedman, A., Seidman, S.: Acute stress facilitates long-lasting changes in cholinergic gene expression. Nature 1998; 393, 373–377.
49. NIH Consensus Conference: The utility of therapeutic plasmapheresis for neurological disorders. JAMA 1986; 256, 1333–1337.
50. Evoli, A., Batcchi, A. P., Provenzano, C.: Thymectomy in the treatment of myasthenia gravis: report of 247 patients. J. Neurol. 1988; 235, 272–276.
Labels
Pharmacy Clinical pharmacologyArticle was published in
Czech and Slovak Pharmacy
2011 Issue 2
Most read in this issue
- Generic substitution, replacement and substitution of drugs: contemporary extent
- Myasthenia gravis – current treatment standards and emerging drugs
- Bacteriocins produced by lactic acid bacteria
- Pelletization of melts and liquids